Aimee Donald, MBChB, PhD, on Assessing PR001 in Children With Type 2 Gaucher Disease

Video

The pediatrician from Royal Manchester Children’s Hospital discussed progress with the PROVIDE trial of PR001.

“We're all kind of waiting desperately to see the outcome of this trial, because I can't think of another trial that has approached GD2 specifically. Certainly, there's nothing else out there at the moment for this patient population. So, it's a really important study, and not just important for GD2 or Gaucher disease, but across lysosomal storage disorders.”

PR001, (Prevail Therapeutics), a single dose, potentially disease-modifying gene therapy, is being evaluated for the potential treatment of infants with type 2 Gaucher disease (GD2), also known as neuronopathic GD, in the phase 1/2 PROVIDE clinical trial (NCT04411654). PR001 is an adeno-associated virus (AAV9) gene therapy administered via intracisternal magna injection.

PR001 aims to address the mutations in the GBA1 gene responsible for Gaucher disease that disrupt the production of beta-glucocerebrosidase and therefore the metabolism of glycolipids, which aggregate α-Synuclein and lead to inflammation and neurodegeneration. The multicenter, open-label study initiated dosing in 2020 and is continuing to enroll up to its target enrollment of 15 participants. Its primary completion date is September 2028.

CGTLive spoke with Aimee Donald, MBChB, PhD, pediatrician, Royal Manchester Children’s Hospital, and professor, University of Manchester, to learn more about the PROVIDE trial. She also discussed the current treatment landscape of GD2 and unmet needs that remain for this population.

REFERENCE
Prevail Therapeutics provides PR001 program update. News release. Prevail Therapeutics. January 9, 2020. https://www.globenewswire.com/en/news-release/2020/01/09/1968680/0/en/Prevail-Therapeutics-Provides-PR001-Program-Update.html
Recent Videos
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Related Content
© 2025 MJH Life Sciences

All rights reserved.